Avant Diagnostics, Inc. Appoints Marcum LLP as Its New Independent Registered Public Accounting Firm

SCOTTSDALE, Ariz., May 12, 2015 (GLOBE NEWSWIRE) -- Avant Diagnostics, Inc. (OTCQXB: AVDX) (the "Company"), a diagnostic company with a primary focus on the commercialization of a proprietary microarray-based diagnostic test for the early detection of ovarian cancer called OvaDx®, is pleased to announce that it has appointed Marcum LLP ("Marcum") as its new independent registered public accounting firm, effective May 4, 2015. Marcum replaces LBB & Associates Ltd., LLP ("LBB"). There were no disagreements between the Company on any matter of accounting principles or practices, financial statement disclosure via, or auditing scope or procedure.

Gregg Linn, the Company's President and Chief Executive Officer, noted, "We are thrilled to have retained Marcum as our new independent registered public accounting firm. With the addition of Marcum and the deep expertise of their team behind us, our ability to now focus on our strategic business initiatives and manage our expected growth is greatly enhanced."

David Bukzin, Partner-in-Charge of Marcum's SEC Practice Group, commented, "Marcum welcomes Avant as a client and looks forward to being a value-added resource as the Company moves forward with its business plan."

About Avant Diagnostics, Inc.

Avant is a medical diagnostic technology company that specializes in first large panel biomarker screening. Our first test, OvaDx®, detects for pre-symptomatic ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Pre-clinical research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA 510K approval, Avant Diagnostics intends to sell or license OvaDx® as a diagnostic test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. Avant intends to utilize its public company stage to expand its portfolio of diagnostic tests in the future.

About Marcum LLP

Marcum LLP is one of the largest independent public accounting and advisory services firms in the United States. Ranked #15 nationally, Marcum LLP offers the resources of 1,300 professionals, including over 160 partners, in 23 offices throughout the U.S., Grand Cayman and China. Headquartered in New York City, the Firm's presence runs deep, with full-service offices strategically located in major business markets. Marcum is a member of the Marcum Group, an organization providing a comprehensive range of professional services spanning accounting and advisory, technology solutions, wealth management, and executive and professional recruiting.

Safe Harbor Statement

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Avant's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Avant does not undertake an obligation to update or revise any forward-looking statement except as required by law. Investors should read the risk factors set forth in Avant's Form 8-K filed with the Securities and Exchange Commission on January 14, 2015, as amended on January 16, 2015, and other periodic reports filed with the Securities and Exchange Commission.

CONTACT: Gregg Linn, President/CEO 480-478-6660 glinn@avantdiagnostics.com Steven Scott 617-448-1300 sscott@scottgrp.comSource:Avant Diagnostics, Inc.